Patient monitoring devices supplier LiDCO increased its product revenues by 10% in the year to July 2019.
Even so, there has also been success in building up SaaS-based high usage programme revenues. The annualised value is £2.1m. There is potential to add to that in the second half, particularly in the US.
Interim revenues fell 4% to £3.5m, but that was due to the loss of a third-party distribution contract. The loss has been reduced and it could halve to £1m for the full year. LiDCO should still have net cash of £1.2m at the end of January 2020.
© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Omega Diagnostics will lose money this year, but it is on course to become profitable in 2020-21 as sales of the VISITECT CD4 test.
House broker Shore Capital has slashed its pre-tax profit forecast for engineer Tricorn Group by two-thirds to £420,000.
Evgen Pharma has entered into an agreement with The University of Dundee for the use of SFX-01 in a clinical trial in non-alcoholic steatohepatitis and liver fibrosis, where there is no existing treatment.